NASDAQ:CRIS Curis Q2 2026 Earnings Results & Report $0.91 0.00 (0.00%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$0.83 -0.08 (-8.44%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Curis beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$4.02 versus the -$6.95 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 14, 2026TimeBefore Market OpensConference Call4:00 PM ET Curis EPS ResultsActual EPS-$4.02Consensus EPS -$6.95Beat/MissBeat by +$2.93One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCuris Revenue ResultsActual RevenueN/AExpected Revenue$1 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCuris' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q3 2026 Earnings ReportConference Call ResourcesQuarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Curis Q2 2026 Earnings FAQ Did Curis beat earnings estimates for Q2 2026? Curis (NASDAQ:CRIS) reported earnings of -$4.02 per share for Q2 2026, beating the consensus estimate of -$6.95. The report was announced on Friday, August 14, 2026. When is Curis' next earnings date? Curis' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Curis on the company's earnings history page. Curis Earnings HeadlinesCuris Faces Nasdaq Delisting Risk After Bid-Price DeficiencyNovember 6 at 5:11 PM | tipranks.comCuris to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026November 5, 2026 | prnewswire.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th. | Behind the Markets (Ad)Curis Shares Surge 70.7% as Reverse Stock Split Vote and Upcoming Clinical Data Attract InvestorsNovember 4, 2026 | finance.yahoo.comWhy Limbach Holdings Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving PremarketNovember 4, 2026 | benzinga.comCuris (CRIS) Expected to Post Earnings on ThursdayOctober 29, 2026 | americanbankingnews.comSee More Curis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Curis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Curis and other key companies, straight to your email. Email Address About CurisCuris (NASDAQ:CRIS) is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation. Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma. As an investigational medicine, emavusertib has not been approved for commercial use. Founded in 2000 and headquartered in Lexington, Massachusetts, Curis has historically advanced drug candidates through internal research and strategic collaborations. The company previously collaborated with Genentech on hedgehog-pathway inhibitors, contributing to the development of Erivedge (vismodegib), which was approved for certain patients with advanced basal cell carcinoma. Curis has also worked with Aurigene Discovery Technologies on the development of emavusertib and related oncology programs.View Curis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?The Ugly Truth Behind SoundHound’s Q3 ResultsSandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater? Upcoming Earnings Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
